Abstract 1568P
Background
Lung cancer (LC) screening is an effective secondary preventive measure in decreasing LC mortality. Except for age and smoking history prediction models with additional variables were verified in different populations. In September 2020 the first pilot program for early detection of LC started in Vojvodina, Serbia. To increase LC positive findings we analyze characteristics of screening participants from September 2020 to April 2024.
Methods
Eligibility for LC screening is restricted to persons aged 50-74 years, with a smoking history of 30 pack-years, or 20 pack-years with additional risks; either active or quit smoking within the previous 10 years. Participants sign informed consent and fill out an online questionnaire with socio-demographic data (age, gender, marital, education, working status), smoking status (pack-years), exposure data (professional, tobacco exposure in childhood, in adulthood), BMI, alcohol consumption, symptoms of respiratory diseases, presence of chronic disease or cancer of other localization, and family history of LC. Screening results were reported by Lung RADS score (1 to 4). Differences between participants with positive (score 4) and negative or intermediate (score 1 to 3) results were analyzed.
Results
During the observed period, 61.3% (1690/2759) of screened were females. Positive screens were reported in 264(9.6%) of participants. Characteristics of participants divided by scores (4 vs score 1-3) showed differences in age (64.03±6.62 vs 61.54±6.71, p<0.001), BMI (25.35±3.87 vs 26.64±4.58, p<0.001), years of smoking (38.82±9.47 vs 37.01±8.60, p=0.001), pack-years (42.59±17.06 vs 39.49±16.20, p=0.003), appetite loss (11.4% vs 6.7%, p=0.005), and weight loss (14.4% vs 8.1%, p<0.001). Significant differences were observed between participants according to employment (p<0.001) and education level (p=0.022); retired (60.6% vs 44.3%) and finished primary school (14.0% vs 8.6%) were more common in score 4, while employed (43.2% vs 27.3%) and faculty education (23.7% vs 19.7%) in score 1-3.
Conclusions
Reaching more elderly and heavy smoker participants with lower BMI and lower education could increase the percentage of LC positive screening results.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Institute for Pulmonary Diseases of Vojvodina.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1607P - Association of the lipid biomarker, PCPro, and clinical outcomes in the ENZAMET trial (ANZUP 1304)
Presenter: Lisa Horvath
Session: Poster session 10
1608P - Prostate cancer working group 4 (PCWG4) preliminary criteria using serial PSMA PET/CT for response evaluation: Analysis from the PRINCE trial
Presenter: Michael Hofman
Session: Poster session 10
1609P - PSMA-PET and PROMISE re-define stage and risk in patients with prostate cancer
Presenter: Wolfgang Fendler
Session: Poster session 10
1610P - Circulating tumour cell (CTC) enumeration and overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC) treated with xaluritamig
Presenter: Andrew Armstrong
Session: Poster session 10
1611P - Haematologic impact of [177Lu]Lu-PSMA-617 versus ARPI change in patients with metastatic castration-resistant prostate cancer in PSMAfore
Presenter: Kim Nguyen Chi
Session: Poster session 10
1612P - Impact of FANCA, ATM, CDK12 alterations on survival in metastatic castration-resistant prostate cancer (mCRPC)
Presenter: David Lorente
Session: Poster session 10
1613P - Clinically advanced prostate cancer (CAPC) featuring BRCA2 loss: A comprehensive genomic profiling (CGP) study
Presenter: Chiara Mercinelli
Session: Poster session 10
1614P - PSA responses and PSMA scan changes after immunotherapy for biochemically recurrent prostate cancer (BCR) without androgen deprivation therapy (ADT)
Presenter: Ravi Madan
Session: Poster session 10
1615P - A new prognostic model of overall survival (OS) in patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC)
Presenter: Susan Halabi
Session: Poster session 10